Literature DB >> 3096556

Distinct functional domains on the recombinant human immune interferon molecule.

M R Ziai, L Imberti, M Kobayashi, B Perussia, G Trinchieri, S Ferrone.   

Abstract

Two monoclonal antibodies directed against distinct epitopes of recombinant human immune interferon (rIFN-gamma) were used to investigate the relationship between the molecular organization of IFN-gamma and its various biological activities on cultured human melanoma cells. Both monoclonal antibodies inhibited the increase in the expression of cell surface human lymphocyte antigens Class I and II antigens and the antiproliferative and antiviral actions of rIFN-gamma. On the other hand neither monoclonal antibody affected the binding of rIFN-gamma to melanoma cells and its ability to reduce the expression of a high molecular weight-melanoma associated antigen. These data indicate that the functional domains of IFN-gamma responsible for antiviral activity, increased human lymphocyte antigen expression and antiproliferative effects on human melanoma cells may be distinct from that (those) involved in reduced expression of the high molecular weight-melanoma associated antigen and in IFN-gamma binding to cell receptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3096556

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

Review 1.  Production of recombinant antibodies using bacteriophages.

Authors:  A M Shukra; N V Sridevi
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-05-21

2.  Human interferon-gamma has three domains associated with its antiviral function: a neutralizing epitope typing scheme for human interferon-gamma.

Authors:  A Y Kwok; X Zu; C Yang; M J Alfa; F T Jay
Journal:  Immunology       Date:  1993-05       Impact factor: 7.397

3.  Interleukin-1 and interferon-γ orchestrate β-glucan-activated human dendritic cell programming via IκB-ζ modulation.

Authors:  Marco Cardone; Amiran K Dzutsev; Hongchuan Li; Nicolas Riteau; Franca Gerosa; Kevin Shenderov; Robin Winkler-Pickett; Lisa Provezza; Elena Riboldi; Robert M Leighty; Selinda J Orr; Folkert Steinhagen; Mark D Wewers; Alan Sher; Stephen K Anderson; Romina Goldszmid; Daniel W McVicar; Lyudmila Lyakh; Giorgio Trinchieri
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.